New hope for Hard-to-Treat cancers: experimental drug enters human testing
NCT ID NCT07100210
First seen Jan 11, 2026 · Last updated May 24, 2026 · Updated 15 times
Summary
This early-stage study tests a new drug called IL-22BP/LNP in people with advanced solid tumors (like sarcoma, head and neck cancer, or melanoma) that have not responded to standard treatments. The main goals are to check the drug's safety and see if it can shrink tumors. Only 6 participants will be enrolled to find the right dose and monitor side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MALIGNANT SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.